304 related articles for article (PubMed ID: 10091817)
1. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure.
Macdonald PS; Keogh AM; Aboyoun CL; Lund M; Amor R; McCaffrey DJ
J Am Coll Cardiol; 1999 Mar; 33(4):924-31. PubMed ID: 10091817
[TBL] [Abstract][Full Text] [Related]
2. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Lancet; 1997 Feb; 349(9049):375-80. PubMed ID: 9033462
[TBL] [Abstract][Full Text] [Related]
3. Impact of concurrent amiodarone treatment on the tolerability and efficacy of carvedilol in patients with chronic heart failure.
Macdonald PS; Keogh AM; Aboyoun C; Lund M; Amor R; McCaffrey D
Heart; 1999 Nov; 82(5):589-93. PubMed ID: 10525515
[TBL] [Abstract][Full Text] [Related]
4. Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function.
Lombardo RM; Reina C; Abrignani MG; Rizzo PA; Braschi A; De Castro S
Am J Cardiovasc Drugs; 2006; 6(4):259-63. PubMed ID: 16913827
[TBL] [Abstract][Full Text] [Related]
5. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
[TBL] [Abstract][Full Text] [Related]
6. Carvedilol improves functional class in patients with severe left ventricular dysfunction referred for heart transplantation.
Pamboukian SV; Aminbakhsh A; Thompson CR; Amin H; Mortimer S; D'yachkova Y; Ignaszweski AP
Clin Transplant; 1999 Oct; 13(5):426-31. PubMed ID: 10515224
[TBL] [Abstract][Full Text] [Related]
7. Baseline predictors of tolerability to carvedilol in patients with chronic heart failure.
Krum H; Ninio D; MacDonald P
Heart; 2000 Dec; 84(6):615-9. PubMed ID: 11083738
[TBL] [Abstract][Full Text] [Related]
8. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
[TBL] [Abstract][Full Text] [Related]
9. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol.
Capomolla S; Febo O; Gnemmi M; Riccardi G; Opasich C; Caporotondi A; Mortara A; Pinna GD; Cobelli F
Am Heart J; 2000 Apr; 139(4):596-608. PubMed ID: 10740140
[TBL] [Abstract][Full Text] [Related]
10. Effects of carvedilol on left ventricular function and oxidative stress in infants and children with idiopathic dilated cardiomyopathy: a 12-month, two-center, open-label study.
Bajcetic M; Kokic Nikolic A; Djukic M; Kosutic J; Mitrovic J; Mijalkovic D; Jovanovic I; Simeunovic S; Spasic MB; Samardzic R
Clin Ther; 2008 Apr; 30(4):702-14. PubMed ID: 18498919
[TBL] [Abstract][Full Text] [Related]
11. Observational cohort study to monitor the use and safety of carvedilol in the treatment of heart failure in clinical practice in England--1st interim report.
Acharya NV; Wilton LV; Shakir SA
Int J Clin Pharmacol Ther; 2005 Jan; 43(1):1-6. PubMed ID: 15704607
[TBL] [Abstract][Full Text] [Related]
12. Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure.
Mortara A; La Rovere MT; Pinna GD; Maestri R; Capomolla S; Cobelli F
J Am Coll Cardiol; 2000 Nov; 36(5):1612-8. PubMed ID: 11079666
[TBL] [Abstract][Full Text] [Related]
13. [Long-term outcome and tolerability of carvedilol therapy in Japanese patients with chronic heart failure].
Kawashiro N; Matsuda N; Endo Y; Uchida Y; Kasanuki H
J Cardiol; 2006 May; 47(5):229-37. PubMed ID: 16764329
[TBL] [Abstract][Full Text] [Related]
14. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Olsen SL; Gilbert EM; Renlund DG; Taylor DO; Yanowitz FD; Bristow MR
J Am Coll Cardiol; 1995 May; 25(6):1225-31. PubMed ID: 7722114
[TBL] [Abstract][Full Text] [Related]
15. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
Takeda Y; Fukutomi T; Suzuki S; Yamamoto K; Ogata M; Kondo H; Sugiura M; Shigeyama J; Itoh M
Am J Cardiol; 2004 Aug; 94(4):448-53. PubMed ID: 15325927
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus.
Nodari S; Metra M; Dei Cas A; Dei Cas L
Eur J Heart Fail; 2003 Dec; 5(6):803-9. PubMed ID: 14675859
[TBL] [Abstract][Full Text] [Related]
17. Use and risk management of carvedilol for the treatment of heart failure in the community in England: results from a modified prescription-event monitoring study.
Aurich-Barrera B; Wilton LV; Shakir SA
Drug Saf; 2009; 32(1):43-54. PubMed ID: 19132804
[TBL] [Abstract][Full Text] [Related]
18. Effects of carvedilol on ventriculo-arterial coupling in patients with heart failure.
Razzolini R; Tarantini G; Boffa GM; Orlando S; Iliceto S
Ital Heart J; 2004 Jul; 5(7):517-22. PubMed ID: 15487269
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure.
Del Sindaco D; Pulignano G; Cioffi G; Tarantini L; Di Lenarda A; De Feo S; Opasich C; Minardi G; Giovannini E; Leggio F
J Cardiovasc Med (Hagerstown); 2007 Sep; 8(9):675-82. PubMed ID: 17700396
[TBL] [Abstract][Full Text] [Related]
20. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment.
Azeka E; Franchini Ramires JA; Valler C; Alcides Bocchi E
J Am Coll Cardiol; 2002 Dec; 40(11):2034-8. PubMed ID: 12475466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
